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Abstract
O-linked N-acetylglucosamine glycosylations (O-GlcNAc) and O-linked phosphorylations (O-phosphate), as two important
types of post-translational modifications, often occur on the same protein and bear a reciprocal relationship. In addition
to the well documented phosphorylations that control Akt activity, Akt also undergoes O-GlcNAcylation, but the interplay
between these two modifications and the biological significance remain unclear, largely due to the technique challenges.
Here, we applied a two-step analytic approach composed of the O-GlcNAc immunoenrichment and subsequent O-
phosphate immunodetection. Such an easy method enabled us to visualize endogenous glycosylated and
phosphorylated Akt subpopulations in parallel and observed the inhibitory effect of Akt O-GlcNAcylations on its
phosphorylation. Further studies utilizing mass spectrometry and mutagenesis approaches showed that O-GlcNAcylations
at Thr 305 and Thr 312 inhibited Akt phosphorylation at Thr 308 via disrupting the interaction between Akt and PDK1.
The impaired Akt activation in turn resulted in the compromised biological functions of Akt, as evidenced by suppressed
cell proliferation and migration capabilities. Together, this study revealed an extensive crosstalk between O-
GlcNAcylations and phosphorylations of Akt and demonstrated O-GlcNAcylation as a new regulatory modification for
Akt signaling.
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Introduction
The serine/threonine kinase Akt, also known as protein kinase
B (PKB), is a central node in cell signaling downstream of growth
factors, and regulates diverse cellular biological functions including
cell proliferation, survival, and metabolism. Aberrant loss or gain
of Akt activation underlies a variety of human diseases, including
diabetes and cancer [1–4]. Because of the important roles of Akt
signaling in cancer, this pathway has been an attractive target for
the development of novel anticancer drugs. However, as Akt signal
is also important for normal cell functions, targeting Akt is likely to
raise serious side effect. Thus, the comprehensive understanding of
the regulatory mechanism of Akt signaling will be of importance to
design better therapeutic strategies [3,5].
Posttranslational modifications (PTM) often play important
roles in regulating protein functions [6,7]. In response to growth
factor stimulation, Akt is recruited to the plasma membrane, and
phosphorylated at Thr 308 by the phosphoinositide-dependent
kinase 1 (PDK1) [8,9] and Ser 473 by the mammalian target of
rapamycin complex 2 (mTORC2) [8,10], respectively. The two
phosphorylations are required for the full activation of Akt [2].
Conversely, the dephosphorylation leads to the termination of Akt
activity. The Thr308 phosphorylation is dephosphorylated by the
protein phosphatase 2A (PP2A) [11,12], and the Ser473
phosphorylation is removed by the PH domain leucine-rich repeat
protein phosphatase (PHLPP) [13]. To date, the phosphorylation
and dephosphorylation mechanism has been thought to primarily
control Akt signaling, but other posttranslational modifications
associated with Akt activity remain poorly known. Until recently,
two new modifications of Akt, monoubiquitination and poly-
ubiquitination, were reported, which were related to the activation
and degradation of Akt, respectively [14,15].
Protein O-GlcNAcylation is a dynamic posttranslational
modification at serine or threonine residues of nuclear and
cytoplasmic proteins, and competes with phosphorylation at the
same or proximal sites. The interplay between O-GlcNAc and O-
phosphate has been implicated in regulating protein function and
plays an important role in the aetiology of chronic diseases, such
as diabetes and cancer [16–18]. In addition to phosphorylations,
Akt also undergoes O-GlcNAc modification [19]. Since its
discovery almost one decade ago, Akt has become one of the
most frequently investigated O-GlcNAcylated target proteins. In
spite of the extensive studies, the relationship between O-
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sial [19–26]. For instance, in 3T3-L1 adipocytes, O-GlcNAcase
inhibitor PUGNAc treatment suppressed the phosphorylation at
Thr 308 [19,20], which, however, failed to be recapitulated by
other two selective O-GlcNAcase inhibitor, NButGT and 6-Ac-
Cas [21,22]. These discrepancies indicate that caution should be
taken when cells are treated with O-GlcNAcase inhibitors or
subjected to OGT overexpression, because ambiguous results
might be obtained and may complicate analyses of the crosstalk
between O-GlcNAcylation and phosphorylation. [27–31].
A recent report described a mass-tagging strategy using
polyethylene glycol tag for O-GlcNAc study, and showed that
the difference of the phosphorylation level between the
glycosylated and non-glycosylated forms of a given protein could
reflect the impact of O-GlcNAcylation on phosphorylation [32].
Based on this conceptual breakthrough, we designed a new
antibody-based approach to directly investigate this crosstalk
independent of the chemical labels. Using this method in
combination with mass spectrometry and Tyr residue simulated
O-GlcNAc modifications, we revealed an extensive and complex
crosstalk between O-GlcNAcylations and phosphorylations of
Akt, showing that O-GlcNAcylations of Akt at Thr 305 and 312
inhibited its phosphorylation at Thr 308 by disrupting the
interaction between Akt and PDK1. Our data suggest that O-
GlcNAcylation represents a new regulator for Akt.
Results
Akt O-GlcNAcylations Inhibit its Phosphorylations
To investigate the interplay between O-GlcNAc and O-
phosphate modifications of Akt, we applied a two-step analytic
approach (Fig. 1A), which allowed us to directly visualize the
endogenous glycosylated Akt and assess its phosphorylation. The
experimental strategy was to fractionate the glycosylated and
nonglycosylated Akt using O-GlcNAc immunoenrichment, fol-
lowed by the immunodetection of phosphorylation using site-
specific antibodies.
Briefly, MCF-7 cells were treated with O-GlcNAcase inhibitor
PUGNAc to facilitate the O-GlcNAcylated proteins enrichment. A
pan-O-GlcNAc antibody was applied for O-GlcNAc immunopre-
cipitation which yielded the O-GlcNAcylated fraction in precipitate
and the supernatant being the un-GlcNAcylated subpopulations.
Then, the global protein amount of the two fractions were adjusted
using atwo-step quantitative immunoblotting analysis (see detailsin
Materials and Methods) to narrow down the amount of the O-
GlcNAcylated Akt to the linear range of immunoblotting analysis
(Fig. 1B), and to ensure the identical total Akt amount between the
O-GlcNAcylated and non-GlcNAcylated subpopulations. The
confirmed Akt level and clean fractionation of O-GlcNAcylated
subpopulations (Fig. 1C) markedly enhanced the credibility of the
phosphorylation assessment afterwards. A simple inspection of the
blotting clearly showed that the phosphorylation levels at Thr 308
and Ser 473 of O-GlcNAcylated Akt were considerably less than
those of un-GlcNAcylated Akt (Fig. 1C), suggesting that the
PUGNAc-induced Akt O-GlcNAc modifications suppressed its
phosphorylations at both Thr 308 and Ser 473. This results were
recapitulated by detecting the constitutively O-GlcNAcylated Akt,
whichimportantlyexcludedthepotentialinterferenceresultedfrom
O-GlcNAcase inhibitors treatment (Fig. 1D and E).
It was noticed that O-GlcNAcylated Akt underwent slight
phosphorylation at Thr 308 and Ser 473 (Fig. 1C and E). While
we could not rule out the possibility of contamination between the
subpopulations samples, it was more likely that Akt bore multiple
O-GlcNAcylation sites and some of them inhibited Akt phosphor-
ylations.
Akt is O-GlcNAcylated at Thr 305, Thr 312, Ser 126 and
Ser 129
To determine which sites of O-GlcNAc modifications inhibited
Akt phosphorylations, we identified Akt O-GlcNAcylation sites by
tandem mass spectrometry. Ectopically expressed Akt was
immunoprecipitated from MCF-7 cells treated by O-GlcNAcase
inhibitor PUGNAc and further purified by SDS-PAGE (Fig. 2A).
Akt bands were in-gel digested with trypsin or Glu-C and the
peptides were analyzed by mass spectrometry [33]. With the
sequence coverage of 85% of human AKT1, we identified four
different O-GlcNAc-modified peptides revealing four O-GlcNAcy-
lation sites.
The two different modified forms of peptides from the
activation loop were identified. Fig. 2B showed one tandem
mass spectrum corresponding to Akt peptide 298–328 containing
two O-GlcNAc residues. In this spectrum, the C-terminal
residues 314–328 were confidently assigned by the presence of
a continuous series of unmodified y-ions (y5–y10 and y12–y16),
suggesting that the two O-GlcNAcylation sites occurred at the N-
terminal part. Furthermore, Thr 312 was deduced as one O-
GlcNAcylation site by the presence of a modified doubly charged
fragment ions y2–20. Fig. 2C showed another tandem mass
spectrum corresponding to Akt peptide 302–328 bearing one
phosphate and two O-GlcNAc moieties. Similarly, the presence
of a continuous series of unmodified y-ions (y3–y16) confirmed
the identity of the C-terminal part of peptide 314–328, thereby
narrowing down the three modifications to the N-terminal part.
Again, the O-GlcNAcylation site at Thr 312 was deduced by the
presence of the modified fragment ions y3–17 (triply charged)
and y3–19 (triply charged). Considering that Thr 308 was
a known phosphorylation site, our results suggested that Thr 305
and 312 were likely two O-GlcNAcylation sites. To verify further
the identified O-GlcNAc sites, we generated site-specific mutants
of Akt at Thr 305 and Thr 312, and examined their O-GlcNAc
levels. Less O-GlcNAc levels were detected on both of single
mutants, particularly T312A, compared to wild type (Fig. 2D).
Moreover, double mutant of T305A/T312A showed much less
O-GlcNAc level (Fig. 2D). This confirmed O-GlcNAcylation sites
of Akt at Thr 305 and Thr312.
We also identified other two O-GlcNAcylated peptides 118–
132 containing two O-GlcNAc residues with or without Met
oxidation, consistently revealing Ser 126 and Ser 129 as two O-
GlcNAc modification sites (Fig. 2E and F). Given that Ser 126
and 129 are also known phosphorylation sites [34,35], the simple
site-directed mutagenesis will be unable to distinguish the
biological functions mediated by either O-GlcNAcylations or
phosphorylations [16]. Together, we have determined four O-
GlcNAcylation sites of Akt: Thr 305 and 312 in the activation
loop, and Ser 126 and 129 at the known phosphorylation sites.
Among the four O-GlcNAcylation sites, Thr 305 and 312 were
particularly intriguing to us, considering that the endogenous O-
GlcNAc-modified Akt exhibited the reduced phosphorylation
level at the proximal Thr 308 (Fig. 1C and E).
O-GlcNAcylations at Thr 305/312 Suppress Akt
Phosphorylation at Thr 308 via Disrupting its Interaction
with PDK1
Distinct from other post-modifications like phosphorylation,
methylation and acetylation, O-GlcNAcylation presents a large
volume of modification. The presence of O-GlcNAcylations has
O-GlcNAcylation, a Negative Regulator for Akt
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the alteration of local conformation. We reasoned that sub-
stitution of O-GlcNAc-modified Thr residue with amino acids
with the relatively large volume of side chain, e.g. Tyr, would
likely simulate the inhibitory effect of O-GlcNAcylation. To test
the possibility of this hypothesis, molecular dynamics (MD)
Figure 1. O-GlcNAcylations of endogenous Akt inhibit Akt phosphorylations at Thr 308 and Ser 473. (A) Schematic representation of
the method for characterization of the interplay between O-GlcNAc and O-phosphate of Akt. The proteins in the cell are first divided into two pools
by O-GlcNAc immunoprecipitation: the un-GlcNAcylated and O-GlcNAcylated proteins subpopulations. Next, the phosphorylation levels of Akt
between the two subpopulations are measured by western blotting. This will directly reflect the effect of O-GlcNAcylations on the phosphorylations
of Akt. Here, MCF-7 cells were serum-starved under PUGNAc treatment (B and C) or under normal conditions (D and E), followed by IGF-1 stimulation
for the indicated times. The un-GlcNAcylated and O-GlcNAcylated proteins subpopulations were prepared. Akt O-GlcNAcylations under PUGNAc
treatment: (B) Determination of the same level of total Akt between the O-GlcNAcylated and un-GlcNAcylated proteins subpopulations. The O-
GlcNAcylated proteins subpopulation was compared to a series of known amounts of the un-GlcNAcylated proteins subpopulations by
immunoblotting against total Akt. (C) Comparison of the phosphorylation levels of the un-GlcNAcylated and O-GlcNAcylated Akt. The un-
GlcNAcylated and O-GlcNAcylated proteins subpopulations were immunoblotted against Akt, O-GlcNAc, and the phosphorylations at Thr 308 and Ser
473. The constitutive O-GlcNAcylations of Akt: (D) Determination of the same level of total Akt between the O-GlcNAcylated and un-GlcNAcylated
proteins subpopulations. The O-GlcNAcylated proteins subpopulation was compared to a series of known amounts of the un-GlcNAcylated proteins
subpopulations by immunoblotting against total Akt. (E) Comparison of the phosphorylation levels of the un-GlcNAcylated and O-GlcNAcylated Akt.
The un-GlcNAcylated and O-GlcNAcylated proteins subpopulations were subjected to immunoblot assay of Akt, O-GlcNAc, and the phosphorylations
at Thr 308 and Ser 473. One unit was equal to 0.01 ml of the un-GlcNAcylated proteins. U: un-GlcNAcylated proteins; O: O-GlcNAcylated proteins.
doi:10.1371/journal.pone.0037427.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37427Figure 2. Identification of Akt O-GlcNAcylation sites at Thr 305, Thr 312, Ser 126 and Ser129. (A) Exogenous Akt was
immunoprecipitated from MCF-7 cells under PUGNAc treatment. The eluted proteins were further separated by SDS-PAGE. Akt bands were in-gel
digested and analyzed by mass spectrometry. (B) Tandem mass spectrum of the triply charged precursor ion at m/z 1300.24 with Xcorr score 2.87.
The spectrum corresponded to Akt peptide 298–328 bearing one oxidation at Met 306 and two O-GlcNAc moieties. The two possible O-GlcNAcylation
sites were Thr 312 and one of Thr 305 and 308. (C) Tandem mass spectrum of the triply charged precursor ion at m/z 1178.97 with Xcorr score 3.29.
This spectrum corresponded to Akt peptide 302–328 containing one O-phosphate and two O-GlcNAc moieties. The two potential O-GlcNAcylation
sites were Thr 312 and one of Thr 305 and 308. (D) O-GlcNAc levels of wild type and mutants of Akt. Akt and its mutants were immunoprecipitated
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sites at Thr 305 and 312 substituted by O-GlcNAc or Tyr
residue, based on the X-ray crystal structure of AKT1 [36]. For
O-GlcNAc modifications, the MD simulations suggested that the
interactions between the phosphothreonine and His194 in the
aC helix, Arg 273 in the catalytic loop and Lys 297 in the
activation loop (A loop) were not preserved any more in both O-
GlcNAc-modified Akt, as compared to wild-type Akt. Mean-
while, the aC helix rotated outward and the A loop refolded in
the O-GlcNAc modifications, partially similar to the depho-
sphorylated conformation (Fig.3A and B in green). For Tyr
substitutions, the modeling results indicated that Tyr 305 H-
bonded with Asp325, and Tyr312 H-bonded with Asp 274 and
Lys 276, similar to the O-GlcNAc modifications (Fig. 3A and B
in pink). Therefore, these results indicated that it was possible
that the local conformational alterations caused by Tyr
substitutions were similar to that caused by O-GlcNAc modifica-
tions and the steric hindrance effect of O-GlcNAcylations at Thr
305 and 312 could, to some extent, be mimicked by Tyr residue.
We next examined whether T305Y and T312Y mutants could
exhibit the similar reduced phosphorylation level at Thr 308 as the
endogenous O-GlcNAcylated Akt (Fig. 1C and E). We observed
that T305Y and T312Y mutants showed the same expression level
as wild type (Fig. 4A). In agreement with the inhibitory effect of O-
GlcNAcylations of endogenous Akt on the Thr308 phosphoryla-
tion (Fig. 1C and E), Tyr mutations at both Thr 305 and Thr
312 almost completely abolished the phosphorylation at Thr 308
stimulated by IGF-1, but no effect was detected for the
phosphorylation at Ser 473, as compared to wild type and
T305A and T312A mutants (Fig. 4 A). Plus, O-GlcNAcylation or
phosphorylation did not occur on Tyr305 or Tyr312 (data not
shown). Thus, these cellular results indicated that Tyr substitution
could simulate the steric hindrance of O-GlcNAcylations at Thr
305 and 312 that inhibited the Thr308 phosphorylation of Akt.
The translocation to the plasma membrane, where Akt is
phosphorylated at Thr 308 by PDK1, is a key step for Akt
activation [8,9]. We next tested whether O-GlcNAcylation affected
the plasma membrane localization of Akt. Immunofluorescence
staining was applied to examine the subcellular localization of
wild-type Akt and the T305 and T312 mutants in COS-7 cells
upon IGF-1 stimulation. We observed that all the mutants and
wild-type Akt translocated to the plasma membrane within 15 min
after IGF-1 stimulation. Indeed, we detected the increased
membrane localization of both T305Y and T312Y mutants
compared to wild-type Akt and the T305A and T312A mutants
(Fig. 4B and 4C). Same results were obtained using subcellular
fractionation followed by immunoblotting analysis. It was impor-
tant to mention that the functional translocation of T305Y and
T312Y mutants upon IGF induction excluded the possibility that
abolished phosphorylation observed above was solely due to the
conformational disruption of the mutants. These results together
indicated that the O-GlcNAcylations caused defect in Akt Thr 308
phosphorylation was unlikely due to the impaired plasma
membrane recruitment.
from MCF-7 cells, and then subjected to western blotting analysis of total Akt and O-GlcNAc level. (E) Tandem mass spectrum of the doubly charged
precursor ion at m/z 981.8 with Xcorr score 2.64. The spectrum corresponded to Akt peptide 118–132 bearing two O-GlcNAc modifications at Ser 126
and Ser 129. (F) Tandem mass spectrum of the doubly charged precursor ion at m/z 989.7 with Xcorr score 2.70. This spectrum corresponded to Akt
peptide 118–132 bearing one oxidation at Met 118 and two O-GlcNAc modifications at Ser 126 and Ser 129. g: O-GlcNAc; o: oxidation, *: possible site
for O-GlcNAcylation or phosphorylation.
doi:10.1371/journal.pone.0037427.g002
Figure 3. Molecular modeling analysis. (A) Molecular modeling of T305Y mutant (pink) and Akt O-GlcNAcylated at Thr 305 (green). Tyr305, O-
GlcNAcylated Thr305 and Asp325 are represented as sticks. (B) Molecular modeling of T312Y mutant (pink) and Akt O-GlcNAcylated at Thr 312
(green). Tyr312, O-GlcNAcylated Thr312, Asp274 and Lys276 are shown as sticks. Additionally, oxygen atoms are shown in red, nitrogen atoms are
shown in blue, and the hydrogen bonds are shown in red dot lines.
doi:10.1371/journal.pone.0037427.g003
O-GlcNAcylation, a Negative Regulator for Akt
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37427O-GlcNAcylation, a Negative Regulator for Akt
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37427Next we investigated whether O-GlcNAcylations at Thr 305 and
312 affected the interaction between PDK1 and Akt. The
coimmunoprecipitation results showed that T305Y and T312Y
mutants had the considerably decreased interaction with PDK1
compared to wild-type Akt, T305A and T312A mutants (Fig. 4D).
Importantly, in vitro PDK1 enzymatic assay showed that T305Y
and T312Y mutants exhibited the significantly reduced phosphor-
ylation level at Thr 308, as compared to wild-type Akt and T305A
and T312A mutants (Fig. 4E). Thus, these studies suggested that
the O-GlcNAcylations at Thr 305 and Thr 312 likely blocked the
access of PDK1 to Thr 308 of Akt and suppressed the subsequent
phosphorylation at Thr 308. Together, these results suggested that
O-GlcNAc modifications at Thr 305 and 312 were associated with
the inhibition of the Thr308 phosphorylation through disrupting
the interaction between Akt and PDK1.
O-GlcNAcylations at Thr 305/312 Down-regulates Akt
Activity
Given that O-GlcNAcylations at Thr 305 and 312 inhibited Akt
phosphorylation at Thr 308 which was thought as the most critical
phosphorylation for Akt activation [5], we sought to determine the
effect of O-GlcNAcylations at these two sites on Akt activities and
functions. We examined the kinase activity of wild type and the
mutants of Akt using an in vitro Akt kinase activity kit, where the
recombinant GSK3-fusion protein containing residues surround-
ing GSK-3a/b (Ser21/9) was provided as an Akt substrate. In line
with the decrease of Akt Thr308 phosphorylation, T305Y and
T312Y mutants exhibited markedly reduced kinase activity
compared to wild-type Akt and the T305A and T312A mutants
by measuring phospho-GSK3 ratio (Fig. 5A). This indicated that
O-GlcNAcylations at Thr 305 and 312 inhibited Akt kinase
activity, thereby in turn likely affecting the biological functions of
Akt mediated by the Thr308 phosphorylation.
Akt is one of the most versatile kinases in human kinome and
controls an array of diverse cellular functions. Cell proliferation is
one of the most prominent biological functions of Akt [2,3].
Consistent to the previous report [15], introduction of wild-type
Akt markedly enhanced the cell proliferation rate of MCF-7 or
COS-7 cells. However, T305Y and T312Y mutants showed
decreased cell proliferation effect compared to wild-type Akt
especially in COS7 cells (Fig. 5B and 5C). These observations
suggested that the presence of O-GlcNAc modifications at Thr
305 and Thr 312 attenuated the Thr308 phosphorylation-
mediated cell proliferation effect of Akt. Cell migration and
invasion are emerging as an intriguing role of Akt [2]. It has
been reported that epidermal growth factor could stimulate the
migration of COS-7 cells [37]. Similar to the previous study, we
observed that introduction of wild-type Akt markedly enhanced
the migration of COS-7 cells, whereas T305Y and T312Y
mutants exhibited the evidently reduced cellular migration
efficacy, as compared to wild-type Akt (Fig. 5D and 5E).
Thus, these results indicated that O-GlcNAcylations at Thr 305
and Thr 312 affected COS-7 cell migration mediated by the
Thr308 phosphorylation of Akt. Furthermore, O-GlcNAc-de-
letion mutants T305A and T312A also showed the moderate
reduction of cell proliferation and migration compared to wild
type (Fig. 5B–E). Thus, it was likely that O-GlcNAcylations at
Thr 305 and 312 could directly regulate the biological functions
of Akt. Together, our results indicated that abnormal O-GlcNAc
modifications at Thr 305 and Thr 312 could down-regulate the
normal activity and functions of Akt.
Discussion
Although the crosstalk between O-GlcNAcylation and phos-
phorylation is getting increasing attention as an important
regulatory mechanism, the progress in understanding this crosstalk
has been highly hindered by the technique challenges. Here, we
provided a useful approach for decoding this important interplay
of an endogenous protein. While our strategy, to some extent,
echoed a recent work by Rexach et al, which successfully visualized
the interplay of a specific protein by introducing a chemical mass
tag [32], our method exhibited two evident features. Firstly, it was
more simplified by employing only commercially available
antibodies and routine laboratory techniques, independent of
techniquely-challenging manipulations such as chemical synthesis
and mass spectrometry; Secondly, the immuno-enrichment
application using an O-GlcNAc antibody allowed us to analyze
O-GlcNAcylated proteins in a very low abundance. This feature
became essential in the case of Akt where only a very small portion
of Akt got O-GlcNAcated, as consistently observed in this study
and previous reports [19]. Moreover, it was also deserved to be
emphasized that the same level of total Akt between the
glycosylated and unglycosylated fractions was determined prior
to the comparison of the phosphorylation levels, as it made the
accurate and straightforward comparison afterwards become
possible. In addition to O-GlcNAcylation, crosstalks between
different types of PTMs such as methylation, acetylation,
ubiquitination and phosphorylation have been widely observed
as the regulatory mechanism of PTMs [38–40]. We believe our
approach provides a simple and effective technique option for
understanding these processes by solely applying the different pan-
or specific- antibodies.
In this study, we applied a tyrosine residue with large volume of
side chain to simulate the bulky steric hindrance of O-GlcNAcyla-
tion, which enabled us to explore the interplay between the site-
specific O-GlcNAcylations and phosphorylations. Such a strategy
was supported by our molecular modeling analysis (Fig. 3),
showing that substitution of O-GlcNAc-modified Thr residues with
Tyr would likely simulate the steric hindrance of O-GlcNAcyla-
tion, though we have been aware of the structural difference
between Tyr and O-GlcNAc. It is conceivable that this strategy is
particularly useful to study the impact of O-GlcNAcylations on
other modifications occurring on the adjacent residues. Impor-
Figure 4. O-GlcNAclyations at Thr 305/312 suppress the Thr308 phosphorylation via disrupting the interaction between Akt and
PDK1. (A) Immunoblot analysis of the phosphorylation levels of wild-type Akt and its mutants. MCF-7 cells were transfected by the indicated
plasmids, followed by IGF-1 stimulation. The cell lysates were subjected to immunoblotting analysis of the phosphorylation levels of Akt. (B)
Fluorescence images of the subcellular localization of Akt and its mutants in COS-7 cells. COS-7 cells were transfected by the indicated plasmids and
serum-starved overnight, followed by IGF-1 stimulation. Cells were fixed and probed by primary Akt antibody. (C) Immunoblot analysis of subcellular
fractions of COS-7 cells expressing wild-type Akt and its mutants in response to IGF-1 stimulation. Na/K ATPase and actin were used as the plasma
membrane and cytoplasmic markers, respectively. PM, plasma membrane; CYT, cytosol. (D) Coimmunoprecipitation assay for the interaction between
PDK1 and Akt or its mutants. MCF-7 cells were transfected by the indicated plasmids and treated by IGF-1. Akt and its mutants were
immunoprecipitated with anti-Flag agarose and the precipitate were probed against Akt and PDK1. (E) In vitro Kinase assay of PDK1. Akt and its
mutants were immunoprecipitated from overexpressed MCF-7 cells and incubated with PDK1 at room temperature. The reaction mixture were
immunoblotted against the Thr308 phosphorylation and total Akt.
doi:10.1371/journal.pone.0037427.g004
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O-GlcNAcylated proteins, p53 [41] and Snail1 [42]. The Tyr
mutants at O-GlcNAcylation sites of both p53 and Snail1 showed
significantly reduced phosphorylation occurring on adjacent
residues, as compared to wild type (Fig. S1A and S1B). By using
T305Y and T312Y mutants of Akt, we observed that the two
mutants reduced phosphorylation levels at Akt Thr 308, consistent
with the findings of endogenous O-GlcNAc-modified Akt (Fig. 1),
further strengthening the credibility of the Tyr mutation strategy
in this scenario. Although well-validated in our study, caution
should be taken when applying this approach to study the
functions of O-GlcNAc modifications in a broader context.
Termination of a signal transduction is as essential as the
activation for all signaling pathways, since the sustained hyper-
Figure 5. Abnormal O-GlcNAcylations down-regulate Akt activity and functions. (A) In vitro Kinase assay of Akt. MCF-7 cells were
transfected by the indicated plasmids and treated by IGF-1. The immunoprecipitated Akt and its mutants were incubated with substrate GSK-3 fusion
protein, followed by immunoblotting against the GSK3a/b(Ser21/9) phosphorylation, Akt phosphorylations and total Akt. (B&C) Cell proliferation
assay of Akt and its mutants. MCF-7 and COS-7 cells transfected by wild-type Akt and its mutants were plated and cultured for the indicated times.
Then, the cells were trypsinized and counted relative to the initially seeded cell number. Representative result was shown from three independent
experiments with similar tendency. (D) Cell migration assay of wild-type Akt and its mutants. COS-7 cells were transfected by wild-type Akt and its
mutants, and were tested using Transwell cell migration assay. The migrated cells were stained by crystal violet. (E) Quantification analysis of cell
migration effect of Akt and its mutants. The stained cells were extracted with a solution of 10% acetic acid, which absorbance at 600 nm was
measured. Cell migration levels were presented as mean 6 s.d. from three independent experiments.
doi:10.1371/journal.pone.0037427.g005
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[20]. In response to growth factor stimulation, Akt is activated and
the phosphorylated Akt translocates to multiple subcellular
organelles and interacts with over 130 substrates of Akt to
transduce the signal to a variety of cellular processes [2].
Accordingly, the organisms have evolved multiple regulatory
mechanisms to terminate the signal transduction of Akt, mainly
including dephosphorylation by phosphatases [5,13] and degra-
dation by proteasome [15]. Here, we demonstrated O-GlcNAc
modification as a new regulatory mechanism for attenuating Akt
activity and functions, which advanced our understanding of the
Akt pathway. Our studies uncovered an extensive and complex
crosstalk between O-GlcNAcylations and phosphorylations of Akt.
We employed the new antibody-based approach in combination
with mass spectrometry and showed that Akt O-GlcNAcylations
could affect almost all the phosphorylations of Akt, including Ser
126, Ser 129, Thr 308 and Ser 473. Moreover, the crosstalk
between O-GlcNAcylations and phosphorylations of Akt was more
complex than the ‘‘yin-yang hypothesis’’ [43], i.e. this interplay
was not the simple binary model with reciprocal on or off status.
On the one hand, O-GlcNAcylations of Akt could remarkably
inhibit the phosphorylations of Akt, likely as the major role of Akt
O-GlcNAcylations. On the other hand, Akt could simultaneously
possess O-GlcNAcylations and phosphorylations, similar to IRS-1
O-GlcNAcylations [44]. Although it is still very difficult to
elucidate the combinational effect of O-GlcNAcylations and
phosphorylation using the existing technologies, the presence of
O-GlcNAcylations will likely affect the biological functions of the
adjacent phosphorylation. Together, our findings have shown that
O-GlcNAcylation is a new regulator for Akt, with the broader roles
in regulating Akt activity than previously speculated. The
combinations of O-GlcNAcylations and phosphorylations will
markedly increase molecular diversity of Akt [16]. These PTMs
of Akt (either single PTM or PTMs in combination) will generate
an array of binding surfaces for effector molecules and the
downstream substrates to mediate the specific biological functions
of Akt [7].
What is the functional contribution of the inhibitory O-
GlcNAcylations to normal Akt signaling? It has been reported
that Akt, PDK1 and OGT co-localize to the plasma membrane
upon the activation of Akt signaling [20], where Akt is
phosphorylated at Thr 308 by PDK1 and O-GlcNAcylated by
OGT. In line with these previous reports, we identified the
constitutive O-GlcNAcylations of Akt in MCF-7 breast cancer
cells. Further, these O-GlcNAcylations under normal conditions
inhibited the phosphorylations of Akt. The level of Akt activity at
steady state should be the result of a balance between activation
and inhibition events. The O-GlcNAcylation levels of Akt under
normal physiological conditions may confer the optimal status for
Akt signal transduction [20]. Therefore, these observations
suggested that O-GlcNAc was necessary for normal Akt signaling.
On the other hand, we utilized Tyr mutation to simulate the
inhibition effect of O-GlcNAcylation. These mutants that
represented an abnormal state of Akt O-GlcNAcylations,
displayed the markedly reduced kinase activity, and in turn
resulted in the significant loss of Akt normal biological functions.
These findings indicated that the aberrant change of the balance
between O-GlcNAc and O-phosphate of Akt would compromise
the normal biological functions of Akt. Therefore, our studies
open up a new avenue to understand Akt signal transduction
through elucidation of the interaction between O-GlcNAcylations
and phosphorylations of Akt.
In summary, we have developed a pair of new strategies to
advance our understanding of the relationship between O-
GlcNAc and O-phosphate of a given protein in complex
biological systems. Our studies reveal an extensive and complex
interplay between O-GlcNAcylations and phosphorylations of Akt
and demonstrate O-GlcNAcylations as a new regulatory modi-
fication for Akt. These findings may have a direct implication in
the regulatory mechanism of Akt signaling.
Materials and Methods
Reagents and Antibodies
Akt, phospho-Akt (Thr308 and Ser473), phospho-GSK3a/
b (Ser21/9), PDK1, Na/K ATPase antibodies were obtained from
Cell Signaling. O-GlcNAc antibody (CTD110.6) was from
Covance. Anti-mouse-IgM agarose, dimethyl pimelimidate, were
from Sigma. O-(2-acetamido-2-deoxy-D-glucopyranosylidene)a-
mino-N-phenylcarbamate (PUGNAc) was obtained from Toronto
Research Chemicals. Complete protease inhibitors cocktail and
phosphatase inhibitors cocktail were obtained from Roche.
Lipofectamine 2000 was obtained from Invitrogen. Anti-Flag
agarose was obtained from Santa Cruz Biotechnology or Sigma.
Cell Culture, Treatments and Transfection
MCF-7 and COS-7 cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and maintained in
DMEM media supplemented with 10% serum. Cells were grown
to 80% confluence and then starved in the absence or the presence
of 100 mM PUGNAc for 24 h, followed by stimulation with IGF-1
(50 ng/ml) for 15 min. A human AKT1 expression vector
pcDNA3-Flag-HA-AKT1 (plasmid 9021) was from Addgene.
Point mutants of Akt were generated with QuickChange site-
directed mutagenesis technique. For cell transfection, MCF-7 and
COS-7 cells were transfected using Lipofectamine 2000 according
to the manufacture’s instruction.
O-GlcNAc Immunoprecipitation and Immunoblotting
The O-GlcNAc antibody CTD110.6 was covalently immobi-
lized to anti-IgM-agarose as described previously [45]. MCF-7
cells were lysed using RIPA lysis buffer containing protease/
phosphatase inhibitors cocktail and PUGNAc. The cell lysate were
incubated with CTD110.6 covalently crosslinked agarose. After
extensively washed, the bound O-GlcNAcylated proteins were
eluted by SDS-PAGE sampling buffer. Meanwhile, the superna-
tant were removed as the un-GlcNAcylated proteins. For western
blotting assay, proteins were resolved by SDS-PAGE and trans-
ferred to nitrocellulose membrane. The corresponding strips of
interest were blotted against the primary antibodies where
indicated.
Purification of Exogenous Akt and In-gel Digestion
MCF-7 cells transfected by wild-type AKT1 were treated by
100 mM PUGNAc for 24 h. Exogenous Akt was enriched by
immunoprecipitation using anti-Flag agarose. The bound proteins
were eluted by SDS-PAGE sampling buffer and further purified by
SDS-PAGE. Akt bands were in-gel digested by trypsin or Glu-C at
37uC.
Mass Spectrometry
LC-MS analysis was carried out on LTQ mass spectrometer
(Thermo). Peptide mixture were separated on a C18 column.
Mass spectrometric data were searched by SEQUST against
human AKT1 protein sequence. The relevant searching param-
eters of mass range, intensity threshold, minimum ioncount,
precursor ion mass tolerance and fragment ion mass tolerance
were set as 500–5000, 500, 15, 3.0 and 1.0, respectively. Trypsin
O-GlcNAcylation, a Negative Regulator for Akt
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cleavages were allowed. Carbamidomethylation of Cys was as
a fixed modification, and phosphorylation (80.0 Da) and O-
GlcNAcylation (203.2 Da) of Ser/Thr, and oxidation of Met
(16 Da) were allowed as variable modifications. All the MS/MS
spectra corresponding to possible O-GlcNAcylated peptides were
manually inspected according to the following criteria: 1) the
fragment ions matched were clearly above baseline noise, 2)
contain sequential series of b- or y-ions, 3) contain the
characteristic fragment peaks of Pro-directed, Asp-directed and
His-directed fragmentation, 4) O-GlcNAc neutral loss. The
identified O-GlcNAcylated peptides were further evaluated
according to the principle of sequence tagging [46].
Molecular Modeling
The O-GlcNAc modifications on Thr 305 and Thr 312 sites
were constructed on the X-ray crystal structure of AKT1 (PDB ID
code: 3CQW), so as the Tyr 305 and Tyr 312 mutants. Molecular
dynamics (MD) simulations were performed on the four systems
plus wild type. MD simulations were carried out with constant
temperature and pressure (NPT) and periodic boundary condi-
tions. The AMBER Parm99 force field was applied for the
proteins. The particle mesh Ewald method was used to calculate
the long-range electrostatics interactions. The nonbonded cutoff
was set to 10.0 A ˚, and the nonbonded pairs were updated every 25
steps. The SHAKE method was applied to constrain all covalent
bonds involving hydrogen atoms. All simulations were coupled to
300 K at 1.0 atm of pressure (atm=101.3 kPa).
Immunofluorescence Microscopy
COS-7 cells were transfected by wild-type Akt and its mutants.
After 36 h, cells were trypsinized and seeded on the coverslips and
starved for 24 h, follows by IGF-1 stimulation for 15 min. The
immunofluorescence assay for Akt was performed as described
previously [20].
Subcellular Fraction
COS-7 cells were transfected by wild-type Akt and its mutants.
After 36 h, cells were starved for 24 h, followed by IGF-1
stimulation for 15 min. The membrane and cytosolic fractions
from the stimulated cells were prepared as described previously
[47].
In vitro Akt and PDK1 Kinase Assays
MCF-7 cells were transfected with wild-type Akt and its
mutants. For Akt kinase assay, cells were starved for 24 h,
followed by IGF-1 stimulation for 15 min. Akt and its mutants
were enriched from the transfected cells using anti-Flag agarose.
In vitro Akt kinase assays were carried out according to the
manufacture’s instruction (Cell Signaling). For PDK-1 kinase
assay, Akt and its mutants were directly immunoprecipitated and
incubated with PDK1 kinase according to the manufacture’s
instruction (Cell Signaling).
Cell Proliferation Assay
MCF-7 and COS-7 cells were transfected with wild-type Akt
and its mutants. After 36 h, the transfected cells were trypsinized
and 5610
5 cells were seeded in 24-well plate. At the culture time
where indicated, cell were trypsinized and directly counted using
automated cell counter. The data were expressed as the pro-
liferation fold relative to the number of the initially seeded cells.
Transwell Cell Migration Assay
COS-7 cells were transfected by wild-type Akt and its mutants.
After 36 h, 1610
5cells were trypsinized and seeded into Transwell
inserts. After 12 h, the upper side of the membrane was rubbed
with cotton swap and the migrated cells in the basal side insert
were fixed and stained with 0.1% crystal violet. The stained cells
were extracted with a solution of 10% acetic acid, which
absorbance was measured at 600 nm. The levels of cell migration
were determined by comparison of the absorbance.
Supporting Information
Figure S1 Tyr substitutions simulate the inhibitory
effect of O-GlcNAcylation of p53 and Snail1. (A) S149Y
p53 mutant shows the significantly reduced phosphorylation level
of p53 at Thr 155. MCF-7 cells were transfected by the indicated
plasmids.Wild type and S149Y mutants of p53 were immunopre-
cipitated with anti-Flag agarose and subjected to immunoblotting
analysis of total p53 and the phosphorylation level of p53 at Thr
155. (B) S122Y Snail mutant shows the significantly reduced
phosphorylation levels of Snail. MCF-7 cells were transfected by
the indicated plasmids.Wild type and S122Y mutants of Snail were
immunoprecipitated with anti-Flag agarose and were immuno-
blotted with total Snail and anti-phospho-serine antibody.
(TIF)
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